KalVista Pharmaceuticals, Inc. (FRA:4XC1)

Market Cap	713.88M
Revenue (ttm)	1.25M
Net Income (ttm)	-177.55M
Shares Out	n/a
EPS (ttm)	-3.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	11.40
Previous Close	11.70
Day's Range	11.40 - 11.40
52-Week Range	6.95 - 14.00
Beta	n/a
RSI	71.05
Earnings Date	Dec 5, 2025

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use ...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Benjamin Palleiko
• Employees: 270
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4XC1

Financial Performance

Financial numbers in USD